Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575878 | PMC |
| http://dx.doi.org/10.4103/aian.aian_234_24 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnosing and treating hypersomnolence in depression.
Sleep Med
December 2024
Department of Psychiatry, McGill University, Montreal, Canada; Centre for Study and Treatment of Circadian Rhythms, Douglas Mental Health University Institute, McGill University, Montreal, Canada.
Hypersomnolence, a broad presentation encompassing excessive daytime sleepiness, hypersomnia and sleep inertia, affects around 25 % of patients with a major depressive disorder. Yet, hypersomnolence is often overlook in clinical settings - which can prevent remission of the mood disorder in addition to significantly interfering with quality of life. Clinical guidelines are lacking to support clinicians in the diagnosis and treatment of hypersomnolence in depression.
View Article and Find Full Text PDFClinical, developmental and serotonemia phenotyping of a sample of 70 Italian patients with Phelan-McDermid Syndrome.
J Neurodev Disord
October 2024
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Background: Phelan-McDermid syndrome (PMS) is caused by monoallelic loss or inactivation at the SHANK3 gene, located in human chr 22q13.33, and is often associated with Autism Spectrum Disorder (ASD).
Objectives: To assess the clinical and developmental phenotype in a novel sample of PMS patients, including for the first time auxometric trajectories and serotonin blood levels.
Efficacy and safety of SENS-401 in sudden sensorineural hearing loss: The AUDIBLE-S randomized placebo-controlled phase IIb trial.
Am J Otolaryngol
December 2024
375 rue du Professeur Joseph Blayac, 34080 Montpellier, France.
Purpose: Safety and efficacy of SENS-401, a serotonin type 3 (5-HT) receptor antagonist and calcineurin inhibitor, in patients with acute sudden sensorineural hearing loss (SSNHL).
Methods: Multicentre randomized, double blind, placebo-controlled trial enrolled adult subjects with sudden sensorineural hearing loss (SSNHL) or unilateral/bilateral acute acoustic trauma leading to SSNHL within 96 h of disease onset. Subjects were randomly assigned to one of the three oral dose groups: 29 mg, 43.
Idiopathic Serotonin Syndrome - Does It Exist?
Ann Indian Acad Neurol
September 2024
Department of Neurology, Smt B. K. Shah Medical Institute and Research Centre Medical College, Sumandeep Vidyapeeth Piparia, Waghodia, Vadodara, Gujarat, India.
Effectiveness and Safety of Flupentixol and Melitracen Tablets for the Treatment of Patients with Persistent Idiopathic Facial Pain: A Retrospective Observational Study.
Pain Physician
May 2024
Department of Pain Management, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Background: Flupentixol and melitracen are being investigated for their potential effectiveness in managing persistent idiopathic facial pain (PIFP), based on their mechanisms of action as dopamine receptor antagonists and noradrenaline/serotonin reuptake inhibitors, respectively. The efficacy and safety of flupentixol and melitracen (FM) tablets in treating PIFP were retrospectively analyzed at our hospital.
Objectives: The aim of this study is to determine the effectiveness and safety of FM tablets in treating PIFP.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!